How to buy Accuray Incorporated stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Accuray Incorporated stock

Own Accuray Incorporated stock in just a few minutes.

Accuray Incorporated is a medical devices business based in the US. Accuray Incorporated shares (ARAY) are listed on the NASDAQ and all prices are listed in US Dollars. Accuray Incorporated employs 932 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Accuray Incorporated

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARAY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Accuray Incorporated share price

Use our graph to track the performance of ARAY stocks over time.

Accuray Incorporated shares at a glance

Information last updated 2021-04-15.
52-week range$1.68 - $6.02
50-day moving average $5.12
200-day moving average $4.40
Wall St. target price$8.20
PE ratio 66.235
Dividend yield N/A (0%)
Earnings per share (TTM) $0.08

Buy Accuray Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Accuray Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Accuray Incorporated under- or over-valued?

Valuing Accuray Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Accuray Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Accuray Incorporated's P/E ratio

Accuray Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Accuray Incorporated shares trade at around 66x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Accuray Incorporated's PEG ratio

Accuray Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.08. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Accuray Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Accuray Incorporated's EBITDA

Accuray Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34 million.

The EBITDA is a measure of a Accuray Incorporated's overall financial performance and is widely used to measure a its profitability.

Accuray Incorporated financials

Revenue TTM $377.3 million
Operating margin TTM 7.12%
Gross profit TTM $149.7 million
Return on assets TTM 3.51%
Return on equity TTM 11.43%
Profit margin 2.03%
Book value $0.84
Market capitalisation $492.2 million

TTM: trailing 12 months

Shorting Accuray Incorporated shares

There are currently 6.4 million Accuray Incorporated shares held short by investors – that's known as Accuray Incorporated's "short interest". This figure is 7.8% down from 6.9 million last month.

There are a few different ways that this level of interest in shorting Accuray Incorporated shares can be evaluated.

Accuray Incorporated's "short interest ratio" (SIR)

Accuray Incorporated's "short interest ratio" (SIR) is the quantity of Accuray Incorporated shares currently shorted divided by the average quantity of Accuray Incorporated shares traded daily (recently around 708197.43589744). Accuray Incorporated's SIR currently stands at 8.97. In other words for every 100,000 Accuray Incorporated shares traded daily on the market, roughly 8970 shares are currently held short.

However Accuray Incorporated's short interest can also be evaluated against the total number of Accuray Incorporated shares, or, against the total number of tradable Accuray Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Accuray Incorporated's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Accuray Incorporated shares in existence, roughly 70 shares are currently held short) or 0.0696% of the tradable shares (for every 100,000 tradable Accuray Incorporated shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Accuray Incorporated.

Find out more about how you can short Accuray Incorporated stock.

Accuray Incorporated share dividends

We're not expecting Accuray Incorporated to pay a dividend over the next 12 months.

Accuray Incorporated share price volatility

Over the last 12 months, Accuray Incorporated's shares have ranged in value from as little as $1.68 up to $6.02. A popular way to gauge a stock's volatility is its "beta".

ARAY.US volatility(beta: 1.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Accuray Incorporated's is 1.9355. This would suggest that Accuray Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Accuray Incorporated overview

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site